T h e serotonin transporter (SERT), which terminates serotonergic neurotransmission by rapid reuptake of 5-hydroxytryptamine (5-HT) back into the nerve terminal was the subject of two studies. First, the regulatory effects of antidepressants on the expression of S E R T was investigated. After chronic exposure of S E R T to antidepressants, substrate transport and antidepressant binding parameters were determined. Long-term exposure of S E R T to a selective 5-HT-re-uptake inhibitor, citalopram, resulted in the down-regulation of the expression level. T h e observed effects depend on drug concentration and exposure time and are Key words: noradrenaline. antidepressant uptake. Abbreviations used: 5-HT, 5-hydroxytryptarnine: HEK-SERT. human embryonic kidney 293 cells that stably express the serotonin transporter; HEK-SmycN. SERT-myc-NET construct stably expressed in human embryonic kidney 293 cells: NE, norepinephrine (noradrenaline): NET, norepinephrine transporter; PKC. protein kinase C: SERT. serotonin (5-hydroxytryptamine) transporter; SSRl selective serotonin re-uptake inhibitor. 'To whom correspondence should be addressed (e-mail shonch(n'as200.zi-rnannheirn.de).
Introduction
In the central nervous system, biogenic monoamine neurotransmitters are transported back into the nerve terminal via specific transporter proteins that belong to a family of Na'/CI--dependent transporters. Among these are the 5-hydroxytryptamine (5-HT; serotonin) transporter (SERT) and the noradrenaline (norepinephrine) transporter (NET). This study focuses on SERT, which plays a crucial role in serotonergic neurotransmission as it controls the concentration of free active neurotransmitter in the synaptic cleft and represents a molecular target for clinically effective antidepressants. Selective serotonin-re-uptake inhibitors (SSRIs) bind to S E R T and enhance synaptic concentrations by blocking 5-HT uptake. Although inhibition of uptake is achieved rapidly and efficiently in eitro, improvement of mood usually occurs in an antidepressant therapy only after 2-3 weeks. Considering the possibility that antidepressant drugs may regulate the activity of S E R T by the induction of longterm adaptive changes and thus, the efficiency of the clearance of 5-HT from the synaptic cleft, the effect of chronic exposure of S E R T to antidepressants was investigated. Rat SERT, stably expressed in a mammalian cell line, was exposed to the antidepressant drugs citalopram (an SSRI) and desipramine (an inhibitor of the S E T ) . After drug treatment, ['HIS-HT transport and [3H]-citalopram binding parameters were determined.
Results similar to those presented here for S E R T have been reported for the regulation S E T by desipramine [ 1,2]. These similarities between the two transporters, as well as their high similarity on an amino acid level (60 "(,) , prompted the present study with the hypothesis that functional molecular mechanisms and regulational mechanisms by specific inhibitors may be identical. Therefore, a study of possible interactions of S E R T and N E T was performed. A concatameric protein, composed of one S E R T monomer and one N E T monomer, was constructed and transfected in a mammalian cell line. However, before studying regulation by specific inhibitors, a detailed analysis of the structure/function relationships was carried out, along with a pharmacological analysis of several inhibitors.
Results and discussion
Regulation of SERT by antidepressants T h e effects of the SSRI citalopram and of the S E T inhibitor desipramine were studied in a heterologous expression system with human embryonic kidney (HEK) 293 cells that stably express the rat S E R T (HEK-SERT). Cells were exposed to different concentrations of citalopram or desipramine [in Dulbecco's modified Eagle's medium supplemented with 10 foetal bovine serum, penicillin (100 U/ml), streptomycin (100 ,ug/ml), and geneticin (G418, 200 ,ug/ml)] for various times before measuring transport rates of or preparing cell membranes for radioligand binding assays [4] . Exposure of the cells to antidepressant concentrations up to 500 nM did not affect cell growth or cell morphology, as assessed microscopically and by counting viable cells after 4 days of incubation. During the incubation, medium was changed daily and, in order as to ensure total removal of antidepressants before performing transport or binding measurements, the cells were incubated for 4 h in drug-free medium and were washed twice with buffer prior to the uptake assay or membrane preparation.
Exposure of HEK-SERT cells to citalopram for 3 days resulted in a decrease in the maximum velocity of 5-HT transport ( V,,,,,) without significant change in substrate affinity (K,) as shown in Figure 1 . This effect was concentrationdependent, with a maximum reduction of V,,, to 38 f 6 "() of control, at a citalopram concentration of 500 nM. An analysis of the time-course of this effect revealed that after a 4 h incubation of HEK-S E R T cells with 500 nM citalopram, V,,, of 5-HT transport was reduced to 55 & 3 " b ; after incubation for 24 h, V,,, is reduced to 4 6 k 3 Ol1 which is not significantly different to the effect observed after a 3 day incubation. Exposure of HEK-SERTcells to 500 n M desipramine resulted in a V,,, of 94 f 4 ',(), compared with the control.
5-HT transport efficiency of HEK-SERT after exposure to different concentrations of citalopram
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This indicates that the observed effect on S E R T activity is specific because a marked reduction was only observed with citalopram treatment. T o evaluate the observed reduction of S E R T activity on a molecular level we analysed the cell surface expression of transporter molecules, by the determination of ['H] means that chronic exposure of HEK-SERT cells to the SSRI citalopram induces a down-regulation of binding sites and, thereby, a reduction of S E R T activity. Comparable findings have been described for other neurotransmitter transporters, which showed a decrease in transport activity accompanied by a reduction in the number of transporter molecules on the cell surface after exposure to transport antagonists : N E T is selectively downregulated after exposure to desipramine [1, 2] , and the activity of the y-aminobutyric acid transporter, G A T l , is reduced after incubation with the specific inhibitor tiagabine [6] . T h e extent of the antagonist-induced down-regulation is similar to that observed upon activation of protein kinase C (PKC). P K C phosphorylates monoamine-, yaminobutyric acid-and glycine-transporters, and upon the activation of PKC it has been shown that V,,,,, (the maximal transport rate) is reduced by approx. SOn,,, with no significant change in K, (the apparent substrate affinity) of these transporters [7-141. In the case of the dopamine transporter, it has been reported that upon activation of PKC the transporters are rapidly endocytosed from the cell surface and targeted to the endosomal/lysosomal pathway, where they are completely degraded [14] . A different mechanism, however, is hypothesized for S E R T after P K C activation. I t has been shown here that S E R T is translocated to intracellular compartments from where it can be redistributed back to the cellsurface upon activation of phosphatases [15, 16] . T h e mechanism by which long-term exposure to antidepressants regulates S E R T or N E T activity is presently unclear.
T h e time course of recovery of ["HIS-HT uptake was measured after incubation of HEK-S E R T cells with 500 nM citalopram for 24-72 h in order to investigate any possible reversibility of the citalopram-induced down-regulation of 5 -H T transport. Different wash-out periods were used since there was no significant difference in V, , , reduction for these incubation times. Cells were incubated with the drug for 24 or 48 h. Medium was changed to drug-free medium and the cells were cultured for a further 24 or 48 hours, after which [3H]5-HT-uptake measurements were performed. Cells were also exposed to citalopram for 72 h and a fourth set of cells was used as drug-free control. As shown in Figure 2 , after a 1 day washout, transport rates were elevated compared with the cells that were exposed to the drug for 72 h, while after 2 days' wash-out the V,,,, values had returned to basal levels. This observation shows that S E R T activity down-regulated by exposure to citalopram can be recovered and it might be an indication for a reversible internalization of transport proteins, implying that endocytosed proteins might be redistributed on the cell surface. T o gain a better insight into molecular mechanisms underlying the effects observed in this study, further analyses on S E R T trafficking and its subcellular distribution after chronic exposure to transport Recovery of basal 5-HT uptake levels following citalopram-induced V,, reduction HEK-SERT cells were exposed to 500 nM citalopram for (A) 24 or (B) 48 h. before changing drug-containing medium to drug-free medium for another 24 (B) or 48 h (A), after which [)H]5-HTuptake measurements were performed One set of cells (C) was exposed to citalopram for 72 h and another set (D) was kept drug-free as a control. Results are expressed as meansfSEM
antagonists are required, along with a detailed investigation of S E R T protein turnover.
Cloning and pharmacological analysis of a concatameric protein of SERT and NET In recent years, different chimeric transporters have been constructed for structure/function analyses. In the case of SERT, for example, 5-HT uptake and radioligand binding assays revealed that rat and human SERTs show different sensitivities to some transporter ligands. Thus, in order to identify the domains or single amino acids of the transporter molecule that are involved specifically in substrate translocation or in antagonist binding, cross-species chimeras between rat and human SERTs were constructed to track the speciesspecific pharmacologies. In these chimeras, parts of the human transporter were exchanged with the corresponding part of the rat transporter [17, 18] .
T o obtain insight into the quarternary structure of SERT, one approach included the functional analysis of concatameric SERTs consisting of two to four S E R T molecules [19] . In order to perform studies on both the structure/function and the quarternary structure, we combined both methods by constructing a chimeric concatamer consisting of S E R T and NET. Therefore, one molecule rat S E R T and one molecule rat N E T was cloned into pcDNA 3.1. T h e first construct that was made had a linker between the Cterminus of S E R T and the N-terminus of NET, which consisted of a part of the polylinker of the cloning vector and had a length of nine amino acids. This construct was transfected in HEK 293 cells and tested for substrate transport. Protein expression was analysed by Western blotting. Uptake tests revealed that transport was functional for both substrates, 5 -H T and norepinephrine (NE). However, Western blots using anti-SERT and anti-NET antibodies identified the presence of single transporter molecules at their monomeric molecular weights. That indicates that the construct is not expressed as a dimeric concatamer on the cell surface. Analysis of the mRNAs of the concatamer by reverse transcriptase-PCR and Northern blotting revealed that the SERT-NET concatamer was transcribed as one RNA molecule and thus, we assume, that the concatameric polypeptide is cleaved by proteases in the cytosol before being inserted into the plasma membrane. Therefore, a second construct containing the mycepitope consisting of an 11 amino-acid linker was cloned. This construct was then stably transfected in HEK 293 cells (HEK-SmycN) and was analysed for functionality and protein expression. Uptake measurements revealed kinetic constants of K , = 1.1 f 0.1 pM and V,,, = 11.2 f 2.0 pmol/mg of protein per min for ['HIS-HT transport and K , = 1.6 f 0 . 3 pM and V,,, = 18.0f 1.2 pmol/mg of protein per min for ['HINE transport. These values are comparable with the constants for the wild-type transporters [20-221. Analysis of the protein by Western blotting using a specific monoclonal mouse antibody against the mycepitope showed a major band with a length of 125 kDa, with no bands visible at the molecular weights of the monomeric transporters. T h e same result was obtained when using antibodies against NET. These findings imply the integrity of the complete HEK-SmycN-construct.
In order to investigate the specificity of substrate transport and antidepressant binding to the concatameric protein, we characterized the pharmacological profile of HEK-SmycN for 5-HT and N E as well as for the antidepressants citalopram (SERT-selective), nisoxetine (NETselective) and imipramine (non-selective). All experiments were carried out in comparison with the wild-type transporter proteins. As seen for 5-HT and NE transport parameters, the inhibition constants obtained for substrate transport inhibition by the antidepressants were comparable with those of wild-type S E R T and NET. In addition, we did not observe any cross-reactivity, i.e. citalopram did not antagonize NE uptake, nor did nisoxetine block 5-HT transport. Therefore, we conclude that substrate transport mediated by HEKSmycN is specific, implying that 5 -H T is transported into the cell by the S E R T component, and NE via the N E T component, and that S E R T and NET, although being physically connected in the concatameric construct do not functionally interact. Whether S E R T and N E T act in the concatameric HEK-SmycN-construct as functional monomers or whether they form homomeric dimers by oligomerization of several concatamers, will be the subject of future studies on the HEKSmycN-construct.
